Akebia's Third Quarter 2026 Financial Results - AKEBIA THERAPEUTICS INC

Explicit Guidance:

• Revenue: Expect continued growth in patient count in Q4 2026; underlying end-user demand for Vafio was estimated between $17–18 million in Q3 and $19–20 million in Q3 (vs. $14.8M actual revenue due to inventory drawdown).
• Pricing/Cost of Therapy: Post-January 1, 2027 (post-TdapA), the expected average annual cost of therapy is projected between $1,000 and $1,500, driven by competitive ESA pricing and lower dosing/compliance factors.
• Peak Revenue: Potential multi-hundred million dollar peak revenue if Vafio becomes standard of care by treating 200,000 to 250,000 patients.
• R&D Expenses: Anticipated increase in R&D expenses for Phase II trials evaluating EBRI and Proli (Prolisaglut).
• Cash Runway: Existing cash resources ($159.3M at quarter-end) plus expected product/cash flows are sufficient to fund the operating plan for at least two years.

Business-Segment Outlook:

• Vafio (Vatadustat):
  • Patient Growth: Expected to continue increasing in Q4 2026, driven primarily by current mid-sized providers (USRC, IRC, DCI) and the anticipated slow rollout from DaVita (starting late 2026, significant ramp early 2027).
  • Adoption Targets: Goal to treat 200,000–250,000 patients to achieve standard-of-care status; currently at ~11,500 patients on therapy (20% of treated patients in mid-size providers).
  • Market Expansion: Avasio (Vatadustat) access expands post-January 1, 2027, to nearly all clinically eligible patients (removing TdapA restriction).
  • Inventory Dynamics: Expect continued inventory reduction as providers minimize stock prior to the January 1, 2027, TdapA expiration.
• Rixia: Revenues expected to decrease in 2026 due to generic competition and pricing pressure.
• Rare Kidney Pipeline:
  • Prolisaglut (PROLI): Enrolling Phase II trial for FSGS; no specific enrollment timing update provided.
  • Ebrevifus (EBRI): Enrolling Phase II basket trial (C3G, IgAN, Lupus Nephritis); initial data expected in 2027. Differentiated by tissue-targeted inhibition with potential for less frequent dosing.

Market and Competitive Outlook:

• Competitive Landscape: DaVita (Mercera shop) and Fresenius are evaluating Vafio; adoption is expected to follow a "domino effect" as DaVita gains experience.
• Pricing Pressure: ESA prices (specifically from Mercera and EPO) are decreasing, exerting downward pressure on Vafio pricing; providers view ESAs as interchangeable at certain price points.
• Utilization Strategy: Vafio adoption will be influenced by the ability to maintain price competitiveness within the bundled payment system while leveraging clinical differentiation (hospitalization reduction).

Macro / Industry Outlook:

• Regulatory/Payment Shift: Transition to post-TdapA landscape (Jan 1, 2027): Vafio reimbursed via dialysis bundle payment; providers can no longer bill separately. This removes prior authorization hurdles for TdapA-only patients but necessitates pricing alignment with bundle economics.
• Clinical Practice Evolution: Recognition of hemoglobin stability and hospitalization benefits (demonstrated in VOICE and Innovate studies) is expected to drive a shift from ESA to Vafio as standard of care over time.
• Market Structure: Dialysis providers (DOs) are the primary decision-makers regarding product selection within bundled payments; payer influence is limited.

Strategic Initiatives:

• Contract Extensions: Negotiating multi-year extensions with DaVita for 2027 and beyond to secure long-term pricing certainty and facilitate rollout.
• Pipeline Advancement: Proceeding with Phase II trials for rare kidney diseases (FSGS with PROLI; Basket with EBRI).
• Personnel Change: Departure of Chief Commercial Officer Nicholas Grund (resigned), now serving as a consultant to finalize contract extensions and drive large DO adoption.
• Clinical Evidence Generation: Continuing analysis of VOCAL study data (dose-TIW non-inferiority) and waiting on health economic analyses for VOICE hospitalization benefits.

Risks and Headwinds to Outlook:

• Adoption Velocity: Slow and deliberate adoption by large dialysis organizations (DaVita, Fresenius) delays revenue realization compared to mid-size providers.
• Operational Factors: Lower-than-expected dialysis compliance rates (patients missing ~1–2 sessions/month) and lower actual drug doses (avg ~810mg vs. expected 900mg) are impacting inventory purchases and revenue recognition.
• Pricing Dynamics: Continued decline in ESA prices (Mercera, EPO) may further compress Vafio pricing below expected levels.
• Regulatory/Market Constraints: The bundled payment system limits revenue growth potential compared to fee-for-service models; reliance on provider internal protocols for dosing and utilization.

Management Tone on the Future:

• Confidence: High confidence that Vafio will become "standard of care" based on clinical outcome data (VOICE trial showing 10% lower hospitalizations).
• Frustration vs. Patience: Acknowledges frustration with the slower-than-expected adoption at large DOs but maintains patience, citing the need for operational readiness and "deliberate" rollout by DaVita.
• Optimism: Expressed optimism regarding the rare kidney disease pipeline, particularly EBRI's potential for differentiation in safety and dosing frequency.

Miscellaneous:

• Stock/Share Count: No specific share count, buyback, or dividend guidance provided.
• Capex: No specific capital expenditure guidance provided; focus remains on funding operations via existing cash and loan refinancing.